Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.

Journal of neurosurgery - 1 Jan 2019

Karsy Michael, Guan Jian, Huang L Eric

Abstract excerpt

OBJECTIVE Gliomas are one of the most common types of primary brain tumors. Recent studies have supported the importance of key genetic alterations, including isocitrate dehydrogenase (IDH) mutations and 1p19q codeletion, in glioma prognosis. Mutant IDH produces 2-hydroxyglutarate from α-ketoglutarate, a key metabolite of the Krebs cycle. The mitochondrial pyruvate carrier (MPC) is composed of MPC1 and MPC2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Cohort Studies
Share to Glioma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isocitrate Dehydrogenase

Share to Kaplan-Meier Estimate

Share to Mitochondrial Membrane Transport Proteins

Share to Monocarboxylic Acid Transporters

Share to Survival Rate

Source

Identifiers

PMID: 29547090
DOI: 10.3171/2017.9.JNS172036

Genes

MPC1
MPC2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.PMID 29547090Read ↗

Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.Semantic proximity Read ↗

Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.Semantic proximity Read ↗

Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical IndicationsSemantic proximity Read ↗

Metabolism of glioma and IDH1/IDH2 mutations.Semantic proximity Read ↗

Isocitrate Dehydrogenase Mutations in Glioma: From Basic Discovery to Therapeutics DevelopmentSemantic proximity Read ↗

A population-based study of high-grade gliomas and mutated isocitrate dehydrogenase 1.Semantic proximity Read ↗

State of the Art in Low-Grade Glioma Management: Insights From Isocitrate Dehydrogenase and Beyond.Semantic proximity Read ↗

Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas.Semantic proximity Read ↗

Clinical prognostic value of isocitrate dehydrogenase mutation, O-6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in glioma patientsSemantic proximity Read ↗

Role of isocitrate dehydrogenase in glioma.Semantic proximity Read ↗

IDH mutations associated impact on related cancer epidemiology and subsequent effect toward HIF-1α.Semantic proximity Read ↗

<p class="MDPI12titleori1" style="mso-line-height-alt: 14.0pt;"><span style="mso-bidi-font-size: 18.0pt;">A Coordinated Mitochondrial Genome Program Predicts Improved Outcome in Lower-Grade GliomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.